Holding(s) in Company

Sep 17, 2018

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsHolding in CompanyHolding(s) in Company
RNS Number : 0208B
Advanced Medical Solutions Grp PLC
17 September 2018
 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Advanced Medical Solutions Group PLC

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify)iii:


3. Details of person subject to the notification obligationiv

Name

BlackRock, Inc.

City and country of registered office (if applicable)

Wilmington, DE, USA

4. Full name of shareholder(s) (if different from 3.)v

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reachedvi:

14/09/2018

6. Date on which issuer notified (DD/MM/YYYY):

17/09/2018

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 8.B 2)

Total of both in % (8.A 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

7.12%

0.27%

7.40%

213,442,312

Position of previous notification (if

applicable)

6.90%

0.31%

7.21%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0004536594


15,211,788


7.12%











SUBTOTAL 8. A

15,211,788

7.12%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
datex

Exercise/
Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

Securities Lending



4,842

0.00%













SUBTOTAL 8. B 1

4,842

0.00%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
datex

Exercise/
Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

CFD



Cash

586,205

0.27%
















SUBTOTAL 8.B.2

586,205

0.27%

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii


Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

See Attachment





10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional informationxvi

 

BlackRock Regulatory Threshold Reporting Team
 
James Michael

020 7743 3650

 

 

Place of completion

12 Throgmorton Avenue, London, EC2N 2DL, U.K.

Date of completion

17 September, 2018

 

 

 

 

 

 

 

 

 

 

Section 9 Attachment

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.




BlackRock Holdco 4, LLC




BlackRock Holdco 6, LLC




BlackRock Delaware Holdings Inc.




BlackRock Fund Advisors




BlackRock Institutional Trust Company, National Association








BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.




BlackRock Holdco 4, LLC




BlackRock Holdco 6, LLC




BlackRock Delaware Holdings Inc.




BlackRock Fund Advisors








BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.




BlackRock International Holdings, Inc.




BR Jersey International Holdings L.P.




BlackRock Group Limited




BlackRock Investment Management (UK) Limited

5.18%

0.27%

5.46%





BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.








BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.




BlackRock International Holdings, Inc.




BR Jersey International Holdings L.P.




BlackRock Holdco 3, LLC




BlackRock Canada Holdings LP




BlackRock Canada Holdings ULC




BlackRock Asset Management Canada Limited








BlackRock, Inc.




BlackRock Holdco 2, Inc.




BlackRock Financial Management, Inc.




BlackRock International Holdings, Inc.




BR Jersey International Holdings L.P.




BlackRock Group Limited




BlackRock Advisors (UK) Limited








 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

HOLUBUVRWVAKAAR

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.